| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 0.12 | 0.0% | 29.4% |
| Total Income | 0.12 | 0.0% | 29.4% |
| Expenditure | 12.09 | 18.9% | 5.3% |
| PBT | — | ||
| Net Profit | -11.26 | 19.2% | 5.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.17 | 19.1% | 32.0% |
Cardiff Oncology Reports Q3 2025 Results; Provides Business Update
04 May 2026 · 4 May, 7:51 am
Summary
Cardiff Oncology announced its third quarter 2025 financial results and provided a business update. The company highlighted positive data from its Phase 2 CRDF-004 trial evaluating onvansertib in combination with standard of care for first-line RAS-mutated metastatic colorectal cancer. As of September 30, 2025, the company reported $60.6 million in cash and investments, projecting a cash runway into Q1 2027. Total operating expenses for the quarter were $12.1 million, a decrease compared to the same period in the previous year. An update from the Phase 2 CRDF-004 trial is expected in Q1 2026.
Key Highlights
- 1
Cardiff Oncology reported positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for first-line RAS-mutated metastatic colorectal cancer.
- 2
The Phase 2 CRDF-004 trial demonstrated a 19% improvement in confirmed objective response rate in the 30mg onvansertib arm compared to the control arm.
- 3
Early progression-free survival data show a trend favoring the 30mg onvansertib arm versus control.
- 4
Cardiff Oncology expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026.
- 5
As of September 30, 2025, Cardiff Oncology had $60.6 million in cash and investments.
- 6
The company projects its cash runway into Q1 2027.
- 7
Total operating expenses for Q3 2025 were approximately $12.1 million, a decrease from $12.8 million for the same period in 2024.
Management Comments
Mark Erlander
This quarter was marked by highly encouraging data from our ongoing CRDF-004 trial evaluating onvansertib in combination with standard of care for first-line RAS-mutated mCRC. At the July 8, 2025 data cutoff, the 30mg onvansertib cohort demonstrated a 19% improvement in confirmed ORR, faster time to response, deeper tumor regression, and early signs of separation in the progression-free survival curves when compared to standard of care alone. The study is on track for the next clinical update in the first quarter of 2026, where we’ll look for a continuation of onvansertib’s favorable tolerability profile and more mature duration of response and progression-free survival data. Onvansertib is uniquely positioned to address a significant medical need and commercial opportunity, with approximately 150,000 new CRC patients diagnosed annually in the U.S. alone. With median progression-free survival of less than 12 months on standard of care and few promising therapies in development for RAS-mutated mCRC, we are optimistic that onvansertib has the potential to redefine first-line care for patients.
Informational and educational content only. Not investment advice.